SCHEMBL7111115

SCHEMBL7111115

Nc1nc(=O)c2c(ncn2Cc2ccc3ccccc3c2)n1Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 1/20 0.44
PDE5A O76074 1/20 0.43
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
CFTR P13569 1/20 0.42
ADORA2A P29274 2/20 0.42
ADORA1 P30542 1/20 0.42
DHFR P00374 1/20 0.41
TYMS P04818 1/20 0.41
CNR2 P34972 2/20 0.40
ACHE P22303 1/20 0.40
PNP P00491 1/20 0.40
SLC29A1 Q99808 3/20 0.39
P2RX4 Q99571 1/20 0.39
NR1I2 O75469 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7111074 0.90 PNP (0.44) MEN1KMT2AADORA2APNP
SCHEMBL7120152 0.89 PNP (0.45) MEN1KMT2AADORA2APNP
SCHEMBL7111860 0.86 PNP (0.45) MEN1KMT2ALMNAADORA2APNP
SCHEMBL7117280 0.86 PNP (0.45) MEN1KMT2ALMNAADORA2APNP
SCHEMBL7110374 0.85 SMN1; SMN2 (0.48) KMT2ALMNAADORA2ATYMSPNP
SCHEMBL6548067 0.85 L3MBTL1 (0.47) L3MBTL1MEN1KMT2ALMNAPDE5A
SCHEMBL7118541 0.83 PNP (0.40) MEN1KMT2AADORA2APNPCASR
SCHEMBL7113849 0.83 PNP (0.43) MEN1KMT2AADORA2APNP
SCHEMBL7113168 0.83 PNP (0.43) MEN1KMT2AADORA2APNP
SCHEMBL7113866 0.83 PNP (0.39) ADORA2APNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186978-A1 Novel telomerase inhibitors PHARMACIA ITALIA, SPA (IT) 2003-10-02 US claimed
WO-2001096339-A1 NOVEL TELOMERASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2001-12-20 WO claimed
US-20030186978-A1 Novel telomerase inhibitors PHARMACIA ITALIA, SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186978-A1 Novel telomerase inhibitors TERT, TERF2IP, TERF2 L3MBTL1 963/4885MEN1 1870/4885KMT2A 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.